RECURSION PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.51 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 169.85K shares, a 97.96% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 264.19K shares, a 101.72% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 3.08M shares, a 20.27% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.51M shares, a 70.74% decline from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 12.00M shares, a 136.00% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 5.08M shares, a 104.70% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.48M shares, a 29.82% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 169.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 169.85K shares derived: sum of 2 quarters · filed 2026-02-25 | 434.04K shares derived: sum of 3 quarters · filed 2026-02-25 | 3.51M shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 264.19K shares derived: sum of 2 quarters · filed 2025-11-05 | 3.34M shares 10-Q · filed 2025-11-05 | 11.65M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 264.19K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 3.34M shares 10-Q · filed 2025-08-05 | 11.65M shares derived: sum of 3 quarters · filed 2025-08-05 | 12.65M shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 3.08M shares 10-Q · filed 2025-05-05 | 11.39M shares derived: sum of 2 quarters · filed 2025-05-05 | 12.38M shares derived: sum of 3 quarters · filed 2025-05-05 | 12.52M shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 8.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | 9.31M shares derived: sum of 2 quarters · filed 2025-02-28 | 9.44M shares derived: sum of 3 quarters · filed 2025-02-28 | 12.00M shares 10-K · filed 2025-02-28 |
| 2024-09-30 | 993.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 1.12M shares derived: sum of 2 quarters · filed 2024-11-06 | 3.68M shares 10-Q · filed 2024-11-06 | 3.68M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 130.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 2.69M shares 10-Q · filed 2024-08-08 | 2.69M shares derived: sum of 3 quarters · filed 2024-08-08 | 2.69M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 2.56M shares 10-Q · filed 2024-05-09 | 2.56M shares derived: sum of 2 quarters · filed 2024-05-09 | 2.56M shares derived: sum of 3 quarters · filed 2024-05-09 | 4.88M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 0.00 shares derived: sum of 2 quarters · filed 2024-02-29 | 2.33M shares derived: sum of 3 quarters · filed 2024-02-29 | 5.08M shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 2.33M shares derived: sum of 2 quarters · filed 2023-11-09 | 5.08M shares 10-Q · filed 2023-11-09 | 5.08M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 2.33M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 5.08M shares 10-Q · filed 2023-08-08 | 5.08M shares derived: sum of 3 quarters · filed 2023-08-08 | 5.09M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 2.76M shares 10-Q · filed 2023-05-08 | 2.76M shares derived: sum of 2 quarters · filed 2023-05-08 | 2.77M shares derived: sum of 3 quarters · filed 2023-05-08 | 3.37M shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 10.88K shares derived: sum of 2 quarters · filed 2023-02-27 | 611.39K shares derived: sum of 3 quarters · filed 2023-02-27 | 2.48M shares 10-K · filed 2023-02-27 |
| 2022-09-30 | 10.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 611.39K shares derived: sum of 2 quarters · filed 2022-11-08 | 2.48M shares 10-Q · filed 2022-11-08 | 3.18M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 600.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 2.47M shares 10-Q · filed 2022-08-09 | 3.17M shares derived: sum of 3 quarters · filed 2022-08-09 | 3.29M shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 1.87M shares 10-Q · filed 2022-05-10 | 2.57M shares derived: sum of 2 quarters · filed 2022-05-10 | 2.69M shares derived: sum of 3 quarters · filed 2022-05-10 | 3.56M shares derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 698.09K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | 815.72K shares derived: sum of 2 quarters · filed 2022-03-23 | 1.69M shares derived: sum of 3 quarters · filed 2022-03-23 | 3.54M shares 10-K · filed 2022-03-23 |
| 2021-09-30 | 117.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 991.16K shares derived: sum of 2 quarters · filed 2021-11-10 | 2.84M shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 873.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | 2.72M shares 10-Q · filed 2021-08-13 | ||
| 2021-03-31 | 1.85M shares 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |